Earnings calls of companies listed in Switzerland ·
Swiss earnings calls, October 28, 2026: UBS expects cost cuts above its ambition
UBS said it expects gross cost reductions of around 13.7 billion US dollars by the end of fiscal year 2026, above its 13.5 billion ambition. Sandoz upgraded its fiscal year 2026 margin guidance to 23%–23.5% of net sales.
An update from FactIQ, written from company statements in earnings calls of companies listed in Switzerland. What is FactIQ?
Key figures
- UBS, expected gross cost reductions by end of fiscal year 2026
- USD 13.7 billionstated by an executive; around this level, above the USD 13.5 billion ambition, after USD 13.2 billion delivered
- UBS, year-to-date return on common equity tier 1 capital, 2026
- 17%stated by the chief executive
- Sandoz, core earnings before interest, taxes, depreciation and amortization margin guidance, fiscal year 2026
- 23%–23.5%stated by the chief executive as an upgrade; fiscal year 2025 margin was 21.7%
- Sandoz, net sales growth guidance, fiscal year 2026
- 5%–6%stated by the chief executive as narrowed; previously mid-to-high single-digit growth
UBS expects to meet or beat its cost, capital and return targets for 2026
UBS held its call for the third quarter of fiscal year 2026.
- The chief executive said UBS is increasingly confident that its 17% year-to-date return on common equity tier 1 capital, a bank's highest-quality capital, will let it outperform its 2026 exit-rate return target.
- The chief executive said UBS remains on track for an exit-rate cost-income ratio, its costs as a share of its income, below 70%.
- An executive said UBS expects gross cost reductions of around USD 13.7 billion (US dollars) by year-end, including USD 0.5 billion in the fourth quarter, after USD 13.2 billion had been delivered.
- An executive said UBS expects its common equity tier 1 (CET1) capital ratio at the end of 2026 to be at or very close to its target of around 14%.
- The chief executive said UBS now expects its 2026 capital returns to exceed pre-acquisition levels. UBS plans to update its 2027 capital-return ambitions in the fourth quarter.
Sandoz narrowed its sales outlook and raised its margin outlook
- The chief executive said Sandoz narrowed its fiscal year 2026 net sales growth guidance to 5%–6%. The chief financial officer said the earlier guidance was mid-to-high single-digit growth, and that the change reflects biosimilar supply constraints and more adverse German market dynamics.
- The chief executive said Sandoz upgraded its fiscal year 2026 core earnings before interest, taxes, depreciation and amortization (EBITDA) margin guidance to 23%–23.5% of net sales. The chief financial officer said the fiscal year 2025 margin was 21.7%.
- The chief financial officer said Sandoz expects to be in its 2028 margin range by 2027, ahead of plan.
Straumann confirmed its 2026 outlook and midterm goal
- An executive said Straumann confirmed its fiscal year 2026 outlook for high-single-digit organic revenue growth and around 140–170 basis points of core earnings before interest and taxes (EBIT) margin improvement at constant 2025 exchange rates.
- An executive said the midterm compound annual growth rate (CAGR) guidance of 10% remains in place.
- An executive said ClearCorrect is on track to reach break-even by the end of 2027, and that Straumann may launch Neodent in China by mid-2027.
Source: Earnings calls of companies listed in Switzerland.